HOME >> BIOLOGY >> NEWS
Malaria drug may treat metabolic syndrome's many symptoms

A drug used for decades to treat and prevent malaria might also fight the many symptoms of metabolic syndrome, a potentially disabling condition that is estimated to affect as many as a quarter of American adults. The findings appear in the November 2006 issue of the journal Cell Metabolism, published by Cell Press.

Researchers, led by Clay F. Semenkovich of Washington University School of Medicine and Michael B. Kastan of St. Jude Children's Research Hospital, found in studies of mice that the antimalaria drug chloroquine improved symptoms of metabolic syndrome; the drug reduced atherosclerosis, lowered blood pressure, and improved blood sugar tolerance. Chloroquine works by activating a particular stress pathway that mediates susceptibility to the syndrome, they found.

"In animals, activating this pathway with extremely low doses of chloroquine counteracted many of the features of metabolic syndrome," said Semenkovich. Semenkovich said he expects to begin a clinical trial of the drug's utility for curbing metabolic syndrome in human patients very soon.

Often associated with insulin resistance, metabolic syndrome can include five components: high triglycerides, low "good" cholesterol, high blood pressure, high blood sugar, and central obesity--characterized in men by a pants waist size of 40 or greater, Semenkovich said. Patients who exhibit three of the five components fit the criteria for metabolic syndrome.

The condition is also associated with atherosclerosis, leaving patients at increased risk of death from cardiovascular disease, the researchers said.

Rather than representing "a unique entity," some have suggested that the metabolic syndrome may simply reflect the cumulative contribution of its components to atherosclerotic risk, the researchers said. An alternative view is that atherosclerosis, insulin resistance, and the component clinical features of the metabolic syndrome share a common unifying mechanism, t
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
7-Nov-2006


Page: 1 2 3

Related biology news :

1. Malaria -- Effective insecticide-repellent synergy against mosquito vectors
2. Malaria-resistant mosquitoes battle disease with molecular warhead
3. Malaria and Epstein-Barr virus linked to pediatric cancer in Africa
4. Malaria in pregnancy: What can the social sciences contribute?
5. Malaria: The right vaccine in the right place?
6. PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine
7. 20 Years of Malaria Research: Outcomes and Perspectives
8. Malaria poses additional risks for first-time mothers
9. Malaria: Efficacy of monotherapies in Cameroon
10. Malaria, potato famine pathogen share surprising trait
11. Malaria parasite impairs key immune system cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/19/2020)... ... June 16, 2020 , ... The director of stem cell biotechnology company ... cell medicine and pharmaceutical industries have easier access to stem cell counting, they will ... of this year, Independence Day weekend in the U.S., Asymmetrex is offering free tissue ...
(Date:6/11/2020)... ... June 08, 2020 , ... Cryo-Cell International’s ... measures to protect workers in the medical field. The face masks will be ... risk their lives every day to provide healthcare to pregnant women. The delivery ...
(Date:6/5/2020)... ... ... Greffex, a pioneering vaccine and gene therapy company based in Houston, Texas, ... for a global perspective to make an impact in a post pandemic world,” said ... an independent, director of the company. , “The Greffex board is excited to have ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... ... June 29, 2020 , ... ... competitively procured purchasing contracts to its membership, recently named BioFit Engineered Products ... with the opportunity to purchase ergonomic seating, cafeteria tables, book trucks and carts ...
(Date:6/28/2020)... ... June 25, 2020 , ... With ... a vaccine or drug treatment. In an effort to better understand the cellular ... the world’s largest imaging dataset portraying therapeutic compound effects from over 1,600 approved ...
(Date:6/23/2020)... ... June 23, 2020 , ... Kerafast Inc. , developers ... announced the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The ... of SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 ...
(Date:6/23/2020)... ... June 22, 2020 , ... Dracen Pharmaceuticals Inc., announced today ... 22-24 during the American Association for Cancer Research Virtual meeting. One poster describes ... consistent single agent activity in KEAP1 mutant tumor models of NSCLC. ...
Breaking Biology Technology:
Cached News: